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Abstract: Pseudomonas aeruginosa is the most prevalent pathogen of cystic fibrosis (CF) 
lung disease. Its long persistence in CF airways is associated with sophisticated mechanisms 
of adaptation, including biofilm formation, resistance to antibiotics, hypermutability and 
customized pathogenicity in which virulence factors are expressed according the infection 
stage. CF adaptation is triggered by high selective pressure of inflamed CF lungs and by 
antibiotic treatments. Bacteria undergo genetic, phenotypic, and physiological variations 
that are fastened by the repeating interplay of mutation and selection. During CF infection 
development, P. aeruginosa gradually shifts from an acute virulent pathogen of early 
infection to a host-adapted pathogen of chronic infection. This paper reviews the most 
common changes undergone by P. aeruginosa at each stage of infection development in 
CF lungs. The comprehensive understanding of the adaptation process of P. aeruginosa 
may help to design more effective antimicrobial treatments and to identify new targets for 
future drugs to prevent the progression of infection to chronic stages. 
Keywords: Pseudomonas aeruginosa; cystic fibrosis; clonal diversification; phenotypic 
variation; mucoid phenotype 
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1. Introduction 
Cystic fibrosis (CF) is an autosomal recessive disease caused by a defect in the cystic fibrosis 
conductance regulator (CFTR) gene located in human on chromosome 7 that mainly affects lungs, 
digestive and reproductive systems, but also the secretory glands, such as the endocrine and sweat 
glands [1]. Although CF is a multi-system disorder causing several complications on the human body, 
its effects on lungs are the best studied so far due to the severe symptoms that patients suffer and high 
mortality rate associated to poor lung function. 
It is generally accepted that CFTR acts as a channel that pumps chloride from the intracellular  
to extracellular space through the membrane of the epithelial cells that produce sputum. Several 
hypotheses have been formulated attempting to explain the relationship between CFTR deficiency  
and sputum accumulation. It has been considered that the transport of chloride partially controls water 
movement and consequently influences the production of thin and flowing sputum, fundamental to 
keeping the lungs protected [1,2]. The CFTR lacks causes, thus, a defective chloride secretion creating 
an osmotic gradient that, consequently, provokes water hyper-reabsorption and abnormal thick and 
sticky sputum [1,3]. This sputum with altered pH interfere with, reducing or even inhibiting the 
activity of epithelial antimicrobial molecules of innate immune system and ciliary functions, both 
crucial for homeostasis. 
Other functions are also associated with CTFR, including inhibition of sodium absorption, of which 
loss causes excessive sodium (and water) absorption, regulation of HCO3
−
 and some proteins transport 
through epithelial cell membranes [3,4]. The relevance of the latter mechanisms in CF airway is unclear, 
however, it is believed that reduced chloride secretion or sodium hyper-absorption can occur. Both 
mechanisms lead to airway-surface-liquid depletion and sputum viscosity increase, causing impaired 
cilia beats and accumulation of thick dehydrated airway sputum, which profoundly accounts for the 
typical symptoms suffered by CF patients [4,5]. The defective mucociliary transport and the compromised 
immune defenses predispose CF patients to the establishment of recurrent bronchopulmonary infections. 
Sputum retention leads to infection and consequently to inflammation, and this circle perpetuates itself 
since inflammatory products, such as elastase released by neutrophils, stimulate sputum secretion and 
breakdown [3,6]. The accumulated sputum is rich in nutrients being, thus, a good environment for 
microbial colonization [7,8]. CF lungs are infected with a complex microbial flora, mainly composed 
by bacteria, provoking acute and chronic infections that result in decline of the lung function, respiratory 
failure, and premature death of patients. Once bacterial infections are established, their eradication by 
antibiotic treatment is hardly ever achieved [9,10]. 
Some progress was made in this field extending the life expectancy of CF patients, however, it 
remains very reduced, around 37 years, mainly because of bacterial infections [11]. In the last decades, 
new therapies have emerged, based on the knowledge of CFTR dysfunction and airway CF microbiome, 
such as targeting CFTR replacement, stimulation of alternative chloride channels, inhibition of sodium 
absorption, and airway rehydration, in order to avoid sputum accumulation and, consequently, the 
establishment of bacterial infections [3–5,12]. None of these strategies has sufficient potential to stop 
CF infections development thus far. The actual and more effective approach to fight CF-associated 
infections relies on antimicrobial treatment. Currently, there is no consensual antimicrobial treatment 
to eradicate bacterial infection from CF lungs [13,14]. Treatments vary among clinics, countries, and 
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even continents. Numerous strategies have been used varying in route of antibiotic administration 
(systemic, oral, inhaled antibiotics, or routes combination), classes of antibiotics, and treatment duration. 
Inhaled antibiotics, mainly aminoglycosides, have high success rates in bacteria eradication, in 
particular against Pseudomonas aeruginosa, due to the direct delivery of high-dose of antibiotic to the 
bronchial lumen space with limited systemic toxicity. For instance, a tobramycin inhalation solution 
has been used to treat long-term and chronic bacterial infection with significant benefits for lung 
function delaying re-infection and reduce mortality [15–17]. Oral and intravenous antibiotics have also 
attracted interest and currently quinolones, in particular ciprofloxacin, are the most used. However, 
ciprofloxacin usage is somewhat limited due to the rapid emergence of resistance. As a solution, 
ciprofloxacin is frequently combined with other antibiotics through other routes of administration. 
Combination of inhaled colistin or inhaled tobramycin with oral ciprofloxacin has been used 
successfully [13]. Some authors had suggested the still used broad-spectrum penicillins and cephalosporins 
in efforts to improve outcomes for CF patients infected with P. aeruginosa [18]. 
Other antibiotics have been introduced and used as alternative agents, such as inhaled amikacin, 
aztreonam lysine, and the combination of fosfomycin and tobramycin [12–14]. However, it has 
assisted to the failure of these antibiotic courses, making urgent the comprehension of the mechanisms 
underlying antibiotic resistance to rapidly define effective strategies to eradicate those infections. 
2. Pseudomonas aeruginosa 
The microbial community resident in CF lungs is known to be complex and it has considerably 
changed, mainly due to alterations in antibiotic regimens. Nevertheless, P. aeruginosa is still the most 
common pathogen isolated from CF sputum, being more prevalent in adults [2,10,19]. 
P. aeruginosa is a versatile microorganism, ubiquitously distributed in different environments, 
including terrestrial, aquatic, animal, human, and plant. It is a Gram-negative opportunist pathogen in 
hospitalized or immune-compromised patients, causing infections, such as pneumonia, burn, wound, 
urinary tract and gastrointestinal infections, otitis media, and keratitis [19,20]. Its versatility arises 
from its large genome, with nearly 6000 genes that enclose, for instance, genes associated with diverse 
metabolic pathways, virulence factors, transport, efflux, and chemotaxis, conferring to P. aeruginosa 
great adaptive ability. Moreover, this bacterium is able to coordinate metabolic pathways, optimize 
nutritional and reproductive potential according to the surrounding conditions and resources and, thus, 
it can survive, grow and cause infection in different environments [20,21]. 
The presence of P. aeruginosa in CF airways is highly associated with poor lung function, 
morbidity and mortality of patients. Despite the inflammatory response and the long-term and intensive 
antibiotic treatments, infections caused by P. aeruginosa persist in CF lungs. Once entering in CF 
airways, P. aeruginosa is virtually impossible to eradicate due to its remarkable genome plasticity that 
allows it to rapidly adapt to the greatly stressful CF environment [2,22,23]. After P. aeruginosa 
colonization, patients may suffer of successive episodes of re-colonization until resulting in a chronic 
infection that can persist from years to decades, or even never eradicated [23,24]. Several factors can 
influence the infection course in CF airways and, unfortunately, there is limited knowledge about the 
characteristics of this microorganism that have impact on the severity of infection. Until now, it is just 
known that during CF infection development, P. aeruginosa switch from an acute environment 
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virulent pathogen, characteristic from early infection stages, to a CF-adapted pathogen, typical of 
chronic infection stages [6,21,25]. This review aimed to provide an overview of the successive 
adaptations that P. aeruginosa undergo, and to describe their impact on long-term persistence in the 
airways. The identification of the genetic background, interactions, and strategies, used by P. aeruginosa 
are crucial, and a prerequisite to develop new approaches for effectively eradicate lung infections. 
3. Sources of Phenotypic Diversification 
The long-term persistence of P. aeruginosa infections in CF lung is associated with clonal 
diversification, or expansion, into specialized phenotypes (Figure 1). Driven by the challenging 
selective pressures imposed by the typical CF conditions, e.g., interspecies competition, deficient oxygen 
availability, biofilm growth, the immune system action, oxidative stress, and antibiotic treatment,  
P. aeruginosa progressively generates phenotypes specially adapted to CF airways conditions [2,9,26,27]. 
The CF selection forces are evident when clinical isolates of P. aeruginosa are frequently mucoid and 
highly resistant to antibiotics. Indeed, mucoid variants are rarely isolated from non-CF environments, 
suggesting the existence of specific CF selective pressure [2,23]. For this reason, P. aeruginosa 
conversion from non- to mucoid form is considered the hallmark of CF airway. 
Figure 1. Time course of P. aeruginosa infection development. (a) Sputum colonization 
stage - P. aeruginosa equipped with full virulence factors enter in CF sputum; (b) Early 
infection stage—P. aeruginosa, which exhibit the environmental or wild-phenotypes 
species characteristics, starts its adaptation to CF environmental conditions; (c) Chronic 
infection stage—P. aeruginosa is full adapted to CF environment. At this stage, there is 
high phenotypic and genotypic diversity and formation of biofilms. 
 
However, other phenotypic features of clonal variants adapted to CF airways have been frequently 
observed, including small colony variants (SCV), non-pigmented variants, increased antibiotic resistance, 
altered metabolic pathways, and attenuated virulence potential [3,22,27]. This phenotypic variation 
occurs for adaptation to the different niches in CF airways. The repeated occurrence of these particular 
phenotypic features and/or gene expression in chronic isolates, sampled from different patients and 
clinical settings, suggests the existence of a parallel evolution of P. aeruginosa in CF airways [28,29]. 
This topic is discussed in detail in Section 4.2. 
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The biofilm-lifestyle represents a reservoir of high phenotypic diversity and it is considered one of 
the most important adaptive mechanisms of P. aeruginosa within CF sputum (Figure 1c) [22,30,31]. 
Worlitzsch et al. (2002) [32] have shown that in the conductive zone, the region from the trachea to the 
terminal bronchiolus, P. aeruginosa grows mainly in biofilms, whereas very few bacteria are localized 
at the epithelial surface of the bronchi. Biofilms are microbial communities encased in self-produced 
matrix composed of exopolysaccharides, proteins and DNA [33–35]. Nowadays, biofilms are recognized 
as an important issue in human disease management due to their notoriously resistance, achieving 10- 
to 1000-fold higher tolerance to antimicrobial agents than corresponding planktonic bacteria [35,36]. 
Biofilm resistance has multifactorial nature resulting from the combination of several mechanisms, 
including restricted penetration of antimicrobials through the exopolysaccharide matrix, slow growth 
of bacteria within biofilms caused by nutrient and oxygen restriction, and accumulated metabolic 
wastes, and quorum-sensing (QS) molecules [37–40]. The limited penetration of antibiotics and immune 
defenses through the exopolysaccharide matrix is definitely a great contributor for their ineffective 
action and P. aeruginosa persistence. Alginate is the major component of CF biofilm matrix providing 
structure and protection to bacteria from the stressful environmental conditions of CF lungs. Augmented 
levels of alginate are generally observed in CF patients chronically infected and it is associated with 
poor prognosis because alginate triggers a vigorous antibody response [41,42]. 
Airway CF biofilms are genetic, proteomic and physiologic different of surface-attached biofilms 
formed, for instance, on indwelling devices (catheters, prostheses, pacemakers, stents), and medical 
and clinical equipment. Instead of the direct surface colonization, clearly observed in device-associated 
infections, bacteria in the CF lungs preferentially form multicellular clusters or macrocolonies within 
the sputum and not on the surface epithelium in the bronchi and non-respiratory bronchioles as initially 
supposed [31,32,43,44]. Additionally, the environment in which CF-associated biofilms are formed is 
considered to be microaerophilic or anaerobic. Bacteria enter and colonize CF sputum, consume oxygen 
via respiration, and generate steep oxygen gradients within the sputum [9,30,44]. The limited oxygen 
availability to potentially anaerobic environments in CF sputum was confirmed by direct in situ oxygen 
measurements using a microelectrode [32]. The oxygen-limited and anaerobic growth conditions 
significantly increase antibiotic resistance of biofilm-forming bacteria [45]. 
Until now, it is not clear what time bacteria after CF airway colonization switch to sessile lifestyle, 
but it is known that biofilm formation enables bacteria to successfully establish chronic infections. 
Presumably, P. aeruginosa form biofilms in response to stressful conditions including microaerophily 
and/or antibiotic treatments [23,46]. 
To switch from planktonic to biofilm mode of growth, bacteria undergo a number of complex 
physiological, metabolic, and phenotypic differentiations. For instance, biofilm-growing bacteria  
undertake specific changes in protein regulation, especially those related with proteins involved in 
resistance to oxidative damage, exopolysaccharide production, phospholipid synthesis, and membrane 
transport [47–49]. Global gene expression analyses of mature P. aeruginosa biofilms have revealed 
1% of differential gene expression between the planktonic and biofilm mode of growth, with 0.5% of 
the genes being activated and about 0.5% being repressed [50]. Among the transcription factors, 
repression of flagellar and pili genes and stress response regulator genes, such as rpoS, 
hyperexpression of genes for ribosomal proteins and metabolism and transport functions were the most 
identified. Interestingly, in the same study, QS-regulated genes were not identified. QS is a cell-cell 
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communication system used by bacteria to regulate gene expression in response to fluctuations in  
cell-population density and it has being reported to play a role in early and later stages of biofilm 
development. P. aeruginosa has two distinct QS systems, termed las and rhl [51,52]. The lack of las 
QS system allowed the formation of biofilms, however, does not allow them to achieve the mature 
stage. The rhl QS system has been reported as active in the early stages of biofilm development and its 
block may prevent biofilm formation [47,53]. Other regulatory systems can influence early stages of 
biofilm development, such as the global virulence regulator GacA [54], the catabolite repression 
control protein Crc [55], and the response regulator proteins AlgR [56]. The blockage by mutation of 
those factors has demonstrated a significant decreased of biofilm formation. 
Gene expression may vary during biofilm development, which means that there is a stage-specific 
temporal and spatial gene expression patterns. This is particular relevant concerning the resistance of 
mature biofilms to antimicrobial treatment. The biofilm-specific phenotype can trigger mechanisms 
responsible for antimicrobial resistance and persistence and consequently enhanced pathogenicity.  
P. aeruginosa genome sequencing have revealed that a mature biofilm can express several cluster 
genes encoding efflux pump involved in resistance to some antibiotics [50]. 
The great variability or heterogeneity of phenotypes included and developed within biofilms is 
certainly one of the major contributors for sessile bacteria recalcitrance that it is not observed in 
planktonic state [57–59]. Within biofilms, various heterogeneous environments exist as a result of the 
distinct levels of nutrients and oxygen availability and accumulated metabolic wastes that bacteria 
have to face and adapt in a process similar to CF airway adaptation [60]. This range of microniches 
with specific biological activities may somewhat be translated by the several distinct colony morphologies 
that biofilm-growing bacteria adopt when grown in a solid media. Such trait diversification profits the 
whole population, with diverse abilities to face environmental challenges, as long as bacteria 
coordinate with each other. Bacterial cooperation and differentiation is facilitated through the 
production and perception of QS small signaling molecules called autoinducers. This interbacterial 
communication is mediated by two types of molecules, N-acylhomoserine lactones (AHL) and  
4-quinolones, allowing bacteria to perceive their density and regulate their gene expressions properly. 
For instance, up-regulating genes encoding virulence factors such as those related to the production  
of enzymes or toxins, optimizes the metabolic and behavioral activities of bacteria within the 
community [61,62]. 
Biofilm heterogeneity is also reflected in distinct antibiotic susceptibility profiles. Due to the different 
biofilm-cell physiological states, biofilms have typically a top-to-bottom decreasing susceptibility 
profile. Antibiotics are effective against the cells located in the top of the biofilm, generally in  
active state, in contrast to the middle and bottom zones, in which cells have reduced or even an 
absence of metabolic activity. Even when antibiotics reach the middle and/or bottom biofilm zones,  
the majority of them have no activity against dormant cells and, thus, are unsuccessful in biofilm 
eradication [39,60,63]. 
Planktonic P. aeruginosa cells are also found in CF sputum [31]. Due to alterations in CF environment, 
such as pH and oxygen and nutrients availability, biofilm-cells dispersion may occur [64]. The 
dispersal of biofilm population provides to P. aeruginosa an opportunity to colonize new zones or 
niches and, thus, perpetuate infection. In fact, dispersal events can be responsible for the acute 
exacerbations observed in chronic infections [46,58,65]. 
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The whole adaptation process to CF airways can be accelerated by the emergence of mutator 
phenotypes (or hypermutable phenotypes) which have high mutation rates up to 1000–fold than  
non-mutator phenotypes [66–68]. In extreme selective conditions, such as those occurring in CF 
airways, this sophisticated mechanism improves the microevolution of P. aeruginosa accelerating its 
intraclonal diversification. The emergence of phenotypic variants and mutators can be intrinsic, relying 
on mutations (or recombinations) caused by defects on one of the several DNA repair or error 
avoidance systems, combined, or not, with extrinsic or environmental factors, such as competition for 
different niches in a spatially heterogeneous environment as CF airways, and/or selection that favors 
any mutant as a better ―fitter‖ to CF airways [67,69,70]. Mutators can also be stimulated by 
environmental factors, such as the presence of reactive oxygen species (ROS) generated from 
inflammatory responses [71]. ROS can trigger the generation of phenotypic variants damaging DNA 
and cause mutations in bacteria. Further, sub-inhibitory or sub-lethal concentrations of antibiotics can 
induce mutations and recombinations and, consequently, supporting the emergence of phenotypic 
variants and mutators [26,67,72]. The genes mainly affected are the antimutator genes mutS, mutL, and 
uvrD but it can be observed defects, as well in the genes mutT, mutM, and mutY [66,73,74]. 
The amount of mutators in biofilms is significantly higher than in planktonic state. This condition may 
explain why biofilm-associated bacteria exhibited enhanced antibiotic resistance, and frequently multidrug 
resistant, and high genetic diversity leading the emergence of diverse phenotypic variants [75,76]. 
The generation of various subclonal variants represents a huge biological advantage because it 
prepares the P. aeruginosa population for extreme and unpredictable stresses (insurance hypothesis) 
supporting the long-term survival of this pathogen [59,77]. Mutators achieve more quickly CF adaptation 
due to the expression of virulence traits, antibiotic resistance, metabolic functions, and increased 
ability to form biofilms, all these features representing a serious clinical problem [67,78,79]. In effect, 
mutators can increase the transcription of genes involved in the metabolism of fatty acids and amino 
acids crucial for obtaining energy in CF ecological niches where aerobic respiration is not possible [80]. 
On the other hand, mutators may have a reduced ability to survive in other distinct environments, 
indicating they can reach high levels of habitat- or niche-specialization spending their biological  
fitness [23,67]. During infection development non- and mutators coexist in CF airways, however, 
mutators prevail at chronic stage, which may be indicative that they have an adaptive advantage. 
The combined action of all these sources of clonal diversification may achieve impressive levels of 
diversification, adaptation, and evolution, promoting the persistence of the bacterial populations in CF 
airways. Therefore, these sources should be intensively studied in order to understand the underlying 
mechanisms to further block them and combat the recalcitrant infections. 
4. P. aeruginosa Evolution and Adaptation during Infection Development 
The regular sampling of CF sputum has allowed performing a detailed characterization of  
P. aeruginosa over infection development through DNA sequencing and other approaches, such as 
transcriptomic, metabolomics and proteomic techniques. Therefore, it is now possible to start drawing 
an evolutionary trajectory of P. aeruginosa within CF airways. 
During infection development genotypes and phenotypes differ markedly from those that initially 
colonized CF airways (Figure 2). Microbiological studies have reported changes in P. aeruginosa 
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phenotypic and genetic traits, relevant in the context of bacterial pathogenesis, and different antibiotic 
resistance patterns along infection development, as well as after antibiotic treatments. Similar evolution 
and adaptation profiles were observed in distinct clonal linages of CF-adapted strains, suggesting that, 
in fact, there is a similar selective pressure in CF airways. This evolution and adaptation processes lead 
to the generation of several phenotypes varying in characteristics, such as colony morphology with 
distinct consistency, size, texture and color, the inactivation of QS, hypermutation, loss of the O-antigen 
components of the lipopolysaccharide (LPS), loss of motility, resistance to antibiotics, changes in 
nutritional requirements, and other virulence-associated traits [2,26,81,82]. In fact, some of those factors 
have been considered the hallmark of CF disease and can determine the infection stage, such as the 
conversion of P. aeruginosa to mucoid phenotype, loss of motility, and the emergence of SCV. 
However, many other characteristics have been described across all phenotypes isolated so far. 
Figure 2. Representation of P. aeruginosa microevolution during infection in CF airways. 
At early stage of infection, P. aeruginosa is full equipped with cell-associated virulence 
factors, including flagella, pili, type 3 secretion systems (T3SS) and secreted virulence 
factors (e.g., proteases, pyoverdine, and rhamnolipid) and exhibit antibiotic sensitivity.  
At the chronic stage of infection, P. aeruginosa is fully adapted to CF environment and 
exhibits a variety of adaptations, including overproduction of alginate, loss of the implicated 
virulence factors for initial infection establishment, are resistant to antibiotics (expression 
of efflux pumps), and adapted metabolism. This microevolution occurs by the repeated 
interplay of mutation and selection.   
 
Antibiotics have provided significant control of bacterial infections in CF airways, however, the 
occurrence of antibiotic resistance and the lack of new drugs or therapeutic strategies make imperative 
the identification of alternative targets for treatment. For understanding the mechanisms underlying 
bacterial adaptation to CF environment and the resistance to antibiotic treatments, an overall picture of 
the actual knowledge about the P. aeruginosa populations, resident in CF lungs, is needed. 
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The compilation of the phenotypic traits exhibited by bacteria according the infection stage is a hard 
task due to the lack of agreement on the definitions of early, intermediate, and chronic colonization 
and infection stages. In this paper, the evolution, adaptation, and diversification profiles of P. 
aeruginosa were reviewed and compared agreed by the ―European Consensus‖ that just considers two 
infection stages, early and chronic stages, according to the presence of P. aeruginosa being lower or 
higher than six months, respectively [83]. 
4.1. Early Infection 
Most CF patients acquired pathogens mainly from environment, especially in clinical settings where 
CF patients remain for long periods of time. For this reason, respiratory infections associated to CF 
patients can be in somewhat considered nosocomial infections. As CF patients acquired environmental 
pathogens, early CF isolates exhibited identical microbial characteristics of their environmental or 
wild-phenotypes species (Figure 2) [21,84,85]. At the first colonization of CF airways, P. aeruginosa 
have to regulate properly its gene expression to quickly adapt to this new environment, including host 
immune defenses, antibiotics, and different substrate composition. 
The bacterial characteristics among CF acute isolates significantly vary, however, there is a trend 
towards high virulence potential and cytotoxicity and lower frequency of mutators strains [86]. The 
expression of virulence factors, including cell-associated and secreted virulence factors, is considered 
to be fundamental at early stage for the success of infection establishment. For instance, (i) the increased 
production of pyoverdine, haemolysin, and phospholipase C; (ii) the augmented production of rhamnolipid, 
regulated by QS, helps biofilm formation that protects cells against oxidative stress, decreases liquid 
surface tension, due to its biosurfactant feature, and facilitates the access to nutrients within biofilms; 
(iii) the increased production of total protease that promotes mucoidy essential for long-term bacterial 
persistence; (iv) the swimming and twitching motilities; and (v) the expression of the type III secretion 
system that augments cell cytotoxicity potential and facilitates infection development [23,84,85,87,88]. 
Typically, P. aeruginosa exhibited a non-mucoid phenotype, sensibility to antibiotics and have low 
bacterial density in lungs in contrast to chronic infections [24,85]. Acute CF isolates produced AHL 
suggesting that QS circuit plays a role for P. aeruginosa pathogenesis at this stage of infection. 
Afterwards, QS seems be no longer needed and lasR mutants are frequently isolated. Mutator strains 
are not prevalent at this stage because they are not efficient to establish a primary infection [51,89]. 
At the early stage, eradication is still possible whether an antibiotic treatment was started as soon  
as possible. Otherwise, 20% of those first P. aeruginosa colonisations could become directly chronic 
infections and may persist up to the end of patient life [24,85]. Following P. aeruginosa eradication,  
it is common a new acquisition event with a different genotype or a re-colonization with the same 
genotype. Re-colonization with the same genotype may occur due to the persistence of the environmental 
source or due to the colonization of the upper airways, such as the paranasal sinuses [90,91]. Upper 
airways can function as reservoirs of pathogens, and interchange of P. aeruginosa can be possible. 
Colonization of the CF airways with mucoid strains is associated with an accelerated rate of decline in 
pulmonary function, however, there is some evidence that early acquisition of mucoid strains could be 
successfully achieved [24,92]. 
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In summary, although the virulence potential of early CF isolates is higher than chronic isolates, 
they exhibited increased antibiotic sensitivity. Therefore, P. aeruginosa early detection and eradication 
are currently the main goal to avoid infection progression to chronic stage. Early infections are 
intensively treated with antimicrobial therapy resulting in P. aeruginosa eradication, at least temporal 
eradication in the majority of patients [24]. In cases of antimicrobial therapy failure, infection can 
shortly evolve to chronic infection. Identification of the CF patients who may evolve to chronic infections 
based on the acute bacterial characteristics is still not possible because of factors related to host-pathogen 
and pathogen-pathogen interactions may play a role and their impact is, thus far, unknown [86,93]. 
4.2. Chronic Infection 
The continuous and selective pressure over the population leads to the emergence of diverse 
phenotypic and genetic variants specially adapted to CF airways. It has been observed, among chronic 
P. aeruginosa isolates, that there are alterations in colony morphology, namely the conversion to the 
mucoid morphotype, to SCV and non-pigmented variants, changes in surface antigens, lack of some 
virulence factors expression, increased antibiotic resistance, overproduction of exopolysaccharides, and 
modulation of microaerobic and anaerobic metabolic pathways (Figure 2). These alterations suggest a 
survival strategy to switch off or, at least, to reduce the expression of some traditional virulence 
factors. In fact, this P. aeruginosa strategy consists in saving or reducing energy costs with virulence 
factors expression in favor of alternative metabolic pathways crucial at this stage. 
The repeated occurrence of these phenotypic features in chronic isolates of P. aeruginosa indicates 
that they may be a result of parallel evolution, which means that related microorganisms develop the 
same adaptive features in identical, but independent, environments [28]. Several transcriptomic studies 
have profiled isolates of P. aeruginosa in attempt to find the common route towards the chronic 
phenotype and the mechanisms underlying such a route. Longitudinal studies using transcriptomic 
approaches have provided relevant information regarding the genetic changes undergo by P. 
aeruginosa and allowed comparing the expression of specific set of genes among patients in different 
periods of time. Gene expression changes in multidrug efflux pumps and regulators of quorum sensing 
and alginate biosynthesis have been identified, being the two latter hotspots of mutations [21,28,94,95]. 
In the scope of genomic evolution in chronic CF lung infection, it should be highlighted that the 
notorious work performed by the Copenhagen and Hanover clinics, which had regularly collected P. 
aeruginosa from the CF lungs of all their patients in the 1970s and 1980s, and performed the genome 
sequencing of the isolates. They started their investigation with the most prevalent clones, the C and 
PA14, and observed that both clones convert their phenotype becoming deficient in the LPS O-antigen, 
with impaired motility and decreased siderophores secretion, as well as in other virulence factors 
expression and remaining non-mucoid [96]. Those isolates later collected just exhibited impaired 
competitive growth. These cases demonstrated that the evolutionary transition might be through the 
additive effects of various mutations. However, a single loss-of-function mutation can induce dramatic 
changes in P. aeruginosa, as those observed through the mucoid variant, due to the pleiotropic effects 
of mucA mutation [2,21]. 
Mucoid colony morphology results from alginate overproduction, absence of flagellin and pilin  
and expression of other virulence factors. Within the mucoid form, P. aeruginosa is more difficult to  
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eradicate because it is highly resistance to antibiotics, as well as to the actions of host immune  
defenses, for instance, to phagocytosis, mediated by macrophages and neutrophils and to antibodies  
oponization [3,30,97]. Alginate overproduction is on the basis of such protection and resistance. 
Alginate promotes P. aeruginosa encapsulation and biofilm formation protecting sessile bacteria from 
the action of ROS, antibiotics and host immune defenses persisting in CF lungs [22,23]. Because 
mucoid P. aeruginosa raise a vigorous antibody response, its presence contributes to tissue damage, 
decreased lung function, and a decline in health [41,42]. The genetic mechanisms underlying  
P. aeruginosa transition to the mucoid form have been intensively studied and conversion is mainly 
caused by mutational inactivation of the mucA gene and rarely of mucB or mucD genes [98,99]. mucA 
gene encodes a cytoplasmatic membrane bound protein that acts as anti-σ-factor, σ22, limiting the 
expression of the algD operon required for alginate synthesis. MucA binds to AlgT (also termed AlgU) 
that negatively controls the transcription of the algD gene. Inactivation of mucA results in upregulation 
of AlgT and production of alginate [2,100,101]. In fact, σ22 can also activate the transcription of 
several other genes related to virulence factor expression and to stress response, including heat shock, 
and osmotic and oxidative stress [21,102]. Additionally, it can repress the expression of type III 
secretion system (T3SS) genes through activation of AlgU that actives the regulatory genes algP, algQ, 
algB, and algR. AlgR, a global regulator, affects the expression of multiple genes including T3SS [103]. 
This suggests an impressive coordination of two high-cost energy systems in order to bacteria persist 
in CF airways. 
Although mucoid phenotype is very successful at chronic infection stage, non- and mucoid phenotypes 
can coexist [31]. Non-mucoid isolates can occur from persistence of P. aeruginosa wild-type or  
re-conversion of mucoid phenotypes (revertants). Mucoid phenotypes can revert to non-mucoid form 
in the absence of in vitro selective pressure or through secondary mutations. Non-mucoid phenotypes 
can also carry mucA mutation, suggesting that mutation occurred when selective pressure occurs and 
when its vanished secondary mutation takes place [21,104]. This suggests that the production of alginate 
represents a high-energy cost and, thus, its unstable feature. At this stage, non-mucoid phenotypes 
have its alginate production at minimal levels [52]. 
The conversion to mucoid phenotype also promotes the biofilm mode of growth. The presence of 
biofilms is a key factor for the persistence of infection in CF airways. Biofilm-cell differentiation and 
dispersal events contribute to the generation of higher diversity that consequently increases the ability 
of P. aeruginosa to colonize new niches in CF airways, thus, perpetuating infection [46,58,59]. 
Another variant frequently isolated from chronic CF lung infections are the SCV. SCV designation 
comes from their small-colony size, typically 1–3 mm after 24–48 h of growth on agar media [105]. 
SCV are normally hyperpiliated, hyperadherent, excellent biofilm formers, and exhibit autoaggregative 
behavior and increased twitching motility [106–109]. In addition, SCV display augmented resistance 
to several classes of antibiotics, notably to aminoglycosides, contributing to their persistence in CF 
airways and poor lung function. SCV are generally selected after prolong antibiotic treatments [105,110]. 
In contrast with the mucoid phenotype, the mutations that arise in SCV appear to be very diverse and a 
challenge for the understanding of the underlying molecular mechanisms [111]. This phenotype may 
arise from the increased expression of the pel and psl polysaccharide gene loci and elevated 
intracellular c-di-GMP levels that enhance the ability to form biofilms, motility, and the expression of 
the type 3 secretion system, persisting, thus, more efficiently in the CF airways [109,111]. Until now, 
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SCV were mostly studied regarding Staphylococcus aureus but, currently, it has been equally assumed 
that P. aeruginosa SCV is, as well, a cause of infection persistence [35,112–114]. 
Other colony morphologies have been isolated from CF airways typically exhibiting rough texture 
due to alteration of the lipid A moiety of LPS. Those variants contain a few, short, or no O side chains 
and exhibited augmented proinflammatory activity [23]. 
In chronic infections, CF isolates typically exhibited impaired motility, namely swimming and 
twitching, due to the absence of flagella and pili, respectively. Lacking flagella (e.g., fliC mutant),  
P. aeruginosa isolates are hardly phagocytosed by alveolar macrophages and neutrophils helping  
to evade the host immune defenses, allowing its persistence in CF airways [23,52]. Moreover,  
P. aeruginosa lives in this chronic stage in biofilm-growth mode in which cells downregulate flagellum 
and type IV pili since they are no longer needed to move across sputum and along epithelial cell 
surfaces [115]. Nonpiliation may arise from mutations of pilB, encoding an ATPase needed for the 
extension and retraction of pili, or defects in pilQ gene, required to extrude the pilus through the 
bacterial outer membrane [116]. Nevertheless, the majority of CF isolates exhibited rpoN mutations 
that provoke the loss of both pili and flagella [117]. 
Chronic CF isolates show other attenuated virulence factors such as reduced production of AHL, 
proteases, phospholipase C, loss of pyoverdine, pyocyanin, and elastase and decreased cytotoxicity 
potential, due to the switching off of the T3SS. These alterations reduce the efficacy of the immune 
system to recognize P. aeruginosa helping, thus, its persistence in CF airways [23,52]. 
Chronic P. aeruginosa isolates are commonly lasR mutants. lasR gene encodes QS transcriptional 
regulator LasR and its downregulation may explain the reduced or absent production of AHL at this 
infection stage, the autolysis and the iridescent gloss of P. aeruginosa colonies, the growth advantage 
on amino acids and decreased virulence potential [94,118]. In addition, lasR mutants can use nitrate 
(NO3
−
) and nitrite (NO2
−
) as the terminal acceptor of electrons allowing P. aeruginosa growth in 
anaerobic niches. The loss of social and cooperative behavior may confer an adaptive advantage  
since the production of QS signal molecules, such as N-(3-oxo-dodecanoyl)-L-homoserine lactone  
(3-oxo-C12-HSL), N-butanoyl-L-homoserine lactone (C4-HSL), 2-heptyl-4(1H)-quinolone (C7-HHQ), 
and 2-heptyl-3-hydroxy-4(1H)-quinolone (PQS), are costly. Avoiding these costs, P. aeruginosa can 
ensure its persistence for the long-term [52,81]. QS seems just contribute to P. aeruginosa 
pathogenesis at colonization or acute stages [81,119]. 
To survive and adapt to CF airways, P. aeruginosa has, as well, to adapt its metabolic pathways.  
In fact, those alterations are also considered a marker of the chronic stage. The generation of energy is 
mainly based on oxidative substrate catabolism, however, P. aeruginosa is able to use alternative 
electron acceptors. The carbon metabolism of P. aeruginosa is mediated by catabolite repression control, 
which determines the catabolism of substrates in a preferred order. Short-chain fatty acids, amino 
acids, and polyamines are generally the preferred carbon sources and sugars the less favored [120]. 
CF sputum contains high amount of mucin, DNA, lipids, amino acids, and proteins that P. aeruginosa 
can uptake. Several studies have reported that peptides, amino acids, and fatty acids belonging to  
host defenses, such as prostaglandins and phosphatidylcholine, supports P. aeruginosa growth in CF 
airways [7,80]. The increased availability of those components is highlighted by the frequent isolation 
of auxotrophic variants for different amino acids, however the adaptive advantage of those variants in 
CF airways is unclear thus far [121]. Arginine and methionine are the most common auxotrophisms 
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detected among CF isolates [122–124]. Auxotrophic variants may be more common than actually reported 
because those variants may be less cultivable in vitro and, consequently, under-estimated. 
As mentioned earlier, the distinct oxygen availability in CF sputum represents a challenge for  
P. aeruginosa, which undergoes metabolic and physiologic changes with a high impact on antibiotic 
treatments. Along chronic infection progress, P. aeruginosa can face aerobic, microaerophilic, and 
anaerobic zones within the CF sputum and different enzymes, transporters, and regulators for different 
metabolic pathways are up-regulated to achieve this adaptation [86]. P. aeruginosa preferentially uses 
oxygen as terminal electron acceptor to obtain maximum energy. However, P. aeruginosa is able as 
well to survive and growth in hypoxic and anoxic CF niches adapting its metabolic pathways. Under 
anaerobic conditions, P. aeruginosa can obtain energy to grow from the denitrification or fermentation  
of arginine [30,80]. Denitrification or anaerobic respiration allows the detoxification of NO, generated 
during infection development. The outer membrane protein, OprF, represents a crucial factor in 
anaerobic metabolism since it allows the permeation of the ions NO3
−
/NO2
−
 fundamental to perform 
denitrification [30,44,80]. In niches where oxygen and N-oxides are unavailable, but amino acids are 
in high amounts, P. aeruginosa can use fermentation of arginine, converting it into ornithine [80]. In 
cases of arginine limitation, P. aeruginosa can still convert pyruvate into acetate and, thus, obtain 
energy. In this way, anaerobic biofilms can be formed and support P. aeruginosa survival, growth, and 
persistence in CF airways. Anaerobic environments increase P. aeruginosa antibiotic tolerance and the 
robustness of biofilms through the increased production of alginate, typically via mutation in  
algT/algU [45,125–127]. Consequently, CF mucoid strains, that are alginate producers, are selected at 
this chronic stage. Despite all these findings about the metabolic pathways used by P. aeruginosa during 
chronic infections, information about the regulation and the mechanisms underlying each metabolic 
pathway and the specific effects on virulence, antibiotic resistance and persistence in CF lungs is still 
scarce. Certainly, the understanding of those mechanisms could help new therapeutic solutions to arise. 
The presence of mutators within the populations are characteristic of chronic infections, considered 
a virulence determinant of P. aeruginosa and often associated with parallel occurrence of subpopulations 
with distinct phenotypic characteristics [66]. Mutators ensure P. aeruginosa survival against various 
CF stress conditions and other unpredictable stress factors, and being, moreover, a key factor in the 
development of multi-antimicrobial resistance [73]. At the chronic stage, hypermutability increases, 
also due to the presence of biofilms, in which the frequency of mutators is higher than the free-living 
mode of growth [75,128]. The transcriptome comparison of a non- and mutator revealed significantly 
transcriptional changes among them. In fact, it was observed that mutators exhibited increased levels 
of genes involved in amino acid and fatty acid metabolism [80]. 
Chronic infections are usually punctuated with acute exacerbations in which P. aeruginosa may 
regain the increased levels of acute virulence of early stages, suggesting that the expression of some 
virulence factors can be reversible [65]. 
Despite the intensive and long antibiotic treatment, chronic infections of P. aeruginosa are rarely 
eradicated due to the occurrence of antibiotic resistance. It is frequently observed β-lactam-resistant  
P. aeruginosa phenotypes, due to the derepression of chromosomal b-lactamase [129], as well  
as ciprofloxacin [130], colistin [131], and tobramycin-resistant phenotypes, and even multi-drug  
resistance [132]. The main reasons for such increased antibiotic resistance is the biofilm-growth style 
and the presence of mutators [73,133–136]. 
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In summary, the exhibition of certain characteristics, including alginate overproduction (mucoid 
phenotype), slow growth, alternative metabolic pathways, antibiotic resistance, and loss of virulence 
factors expression, is currently considered a chronic phenotypic profile and the end-point result of  
P. aeruginosa evolution in CF airways. P. aeruginosa clearly adopts a strategy aiming to reduce its 
energy costs in favor of activation of other biological pathways that ensure its long-term persistence. 
The actual evolutionary ―model‖ of P. aeruginosa within CF airways consists in an initial and rapid 
adaptation period dominated by positive selection and adaptive mutations, followed by a period with 
minor phenotypic changes dominated by negative selection and fewer adaptive mutations [2]. This 
evolutionary process ends with an advent of a lineage of highly adapted bacteria with impressive 
ability to persist in CF lungs for long-term. Despite the assumption of parallel evolution to CF-well 
adapted phenotypes and the limited number of adaptive features, it is important to highlight that the 
actual evolutionary route towards a common profile among different patients is still not well understood. 
In fact, genomic and transcriptomic studies have just begun tracking P. aeruginosa evolution. 
5. Conclusions 
The study of the adaptation process and dynamical evolution of P. aeruginosa within CF lungs, and 
its impact on bacterial pathogenicity and virulence, is currently a topic of most importance in disease 
management. In this paper, the most common evolutionary profile of P. aeruginosa reported by 
researchers and clinicians were reviewed, however, other evolutionary, phenotypic, and genotypic 
profiles can be found in different demographic locations, clinics, and patients. 
Longitudinal studies of clonal variants of different CF patients have tried to identify a common 
―expression signature‖ of P. aeruginosa over time. Genome sequencing, transcriptomic, and proteomic 
analysis have advanced the understanding of P. aeruginosa evolution, epidemiology and response to 
CF stress conditions, however there is still limited information about such ―expression signature‖. 
During adaptation, P. aeruginosa undergoes complex, structural and dynamic changes over the time. 
CF isolates from acute infections differs poorly from non-CF environment in contrast to the isolates 
from chronic infections that have been interpreted as the result of P. aeruginosa adaptation to CF 
airways. Depending on the early antibiotic treatment, infection, sooner or later, will evolve to chronic 
infection. The CF lung adaptation of P. aeruginosa is characterized by the transition from an acute 
environmental pathogen to a chronic CF-well-adapted pathogen, and the emergence of a phenotypically 
heterogeneous population. To establish chronic infections, P. aeruginosa loses some of its virulence 
potential (production of enzymes and toxins and lack of QS), slows down its growth rate, increases its 
antibiotic resistance (often multi-drug resistance), and/or reduces the stimulation of the immune system 
mainly due to a switch to the biofilm mode of growth, favored by overproduction of alginate. 
Typically, chronic P. aeruginosa isolates exhibited mucoid phenotype due to the overproduction of 
alginate and lack of flagella and pili. The presence of mutators in CF resident population is not strictly 
necessary to achieve adaptation, however, it represents a very large biological advantage in contrast 
with irreversible and accumulative mutations. Diversification of the metabolic pathways plays a 
fundamental role in the establishment of chronic infections in CF airways. In effect, P. aeruginosa can 
grow in microaerophilic and anaerobic zones by adjusting its metabolism. Denitrification, arginine 
fermentation and consumption of fatty acids are alternatives pathways to survive and growth in CF. 
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Future investigations should address the mechanisms underlying P. aeruginosa adaptation to CF 
airways to better understand them and to help design new therapeutic strategies. Studies about  
P. aeruginosa pathogenesis at early stages should be, especially, investigated more as the better way to 
avoid chronic infections is not allow their progression. 
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